Strand and Elan Enter Into Research Collaboration
News Sep 30, 2005
Strand Life Sciences has announced that it has entered into a research collaboration with Elan Pharmaceuticals aimed towards supporting Elan's drug discovery efforts.
This collaboration allows Elan to access Strand's technologies and achieve customized solutions for internal research programs.
The agreement incorporates access to Strand's extensive in silico technology portfolio including predictive modeling for efficacy and ADMET, custom library design, QSAR and pharmacophore modeling, structure based drug design, data and visual mining and consulting experience.
“We believe that Strand's portfolio of technologies are leading edge and look forward to working with them to advance our discovery efforts,” said Dale Schenk, Chief Scientific Officer, Elan Pharmaceuticals.
“We are very excited about this opportunity and are confident that this will be a mutually beneficial relationship,” said Kas Subramanian, Ph.D., CSO of Strand Life Sciences.
“Our existing technology platform coupled with our consulting experience allows us to rapidly develop and deploy tailored solutions that enable decision making.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019